CD52 and mantle cell lymphoma: Primary mantle cell lymphoma cells collected from patients at first diagnosis and from one patient after relapse (P3) were included to study the effect of treatment with ibrutinib and CD52 mAb (8 peripheral blood mononuclear cell (PBMC), 2 lymph node, and 2 healthy control PBMC samples; see Supplementary Table 2 for patient characteristics).